- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02967302
NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee Joint
NEUROIMPA "Intraarticular Application of Opioids in Chronic Arthritis"
To investigate pain and inflammatory parameters (cytokines, immune cells) in knee joint tissue of chronic arthritis patients following intraarticular (i.a.) injections of morphine, a standard steroid or placebo.
The primary hypothesis is that i.a. morphine results in significantly lower pain scores and supplemental analgesic consumption than placebo during the first week after injection, an efficacy comparable to standard i.a. steroid (triamcinolone) medication.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3 arm, double blind, placebo controlled, prospective, mo-nocenter study, which will be conducted in the Department of Rheumatology, Charité University Medicine Berlin, Cam-pus Benjamin Franklin in collaboration with several rheu-matology and orthopedic practices in the Berlin area. Ultra-sound guided synovial needle biopsy and interventions will only be performed at CBF.
Eligible patients will be treated with either morphine 3 mg i.a., NaCl 0.9% i.a. or triamcinolone 40 mg i.a. at Baseline. The entire study period will be 2 weeks per patient.
Assessment of the primary outcome parameter will be at week 1. The patients will be monitored closely throughout the entire study period with a total of 4 visits (screening, baseline, week 1, week 2).
Safety data will be collected in the adverse events form, vital parameters, physical examination and laboratory tests dur-ing the whole study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12203
- Charité CBF Rheumatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically detectable and/or ultrasound-visible knee ef-fusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Col-lege of Rheumatology, ACR criteria), undifferentiated mono- or oligoarthritis, Osteoarthritis of the knee, OA.
- baseline pain score (on a 100 mm Visual Analogue Scale, VAS) >40 mm;
- male and female patients, age ≥18 - 80 years,
- body weight 50 - 90 kg.
- Able and willing to give a written informed consent and comply with the requirements of the study protocol. Only patients who give written informed consent will be in-cluded in the trial.
- If female: either not of child-bearing potential (meno-pausal since 1 year or surgically sterile) or is willing and able to practice a reliable method of contraception throughout the study with a pearl index <1. Reliable methods of contraception are: condoms plus other methods: implants, injecatbles, combined oral contracep-tives, intrauterine devices, initiated at least 90 days prior to screening. Further reliable methods are a vasecto-mised partner (at least 1 year prior to enrolment), sexual-ly abstinent, surgically sterilized (including hysterecto-my), postmenopausal defined as at least 1 year of spon-taneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle stimulating hormone (FSH) above 40 U/l and estradiol below 30 nl/l is confirmatory).
- If male: either not of child-bearing potential (surgically sterilized, e.g. vasectomy) or is willing and able to prac-tice a reliable method of contraception with a pearl index <1 (see inclusion criterium 6) throughout the study.
Exclusion Criteria:
- Severe cardiovascular, respiratory, metabolic, neurologi-cal, psychiatric disorders; current bacterial infection es-pecially of the knee
- abuse of analgesics, benzodiazepines, alcohol; "hard drugs"
- pregnancy, lactation
- before biopsy thrombocyte count < 100/nl, Quick <50%
- intake of anticoagulants, anti-aggregants as monothera-py such as ASS 100 will be allowed
- participation in an investigational trial during the last 30 days or 5 HLT whichever is longer
- treatment with intraarticular steroids during the past 4 weeks in the selected joint.
- Patients with a history of a severe psychiatric illness, which might interfere with the patient's ability to under-stand the requirements of the study and assessment.
- Patients who are institutionalised due to regulatory or juridical order. Patients who are an employee of the in-vestigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
- Known hypersensitivity to any component of the study medication to morphine or triamcinolone, ileus, respira-tory depression, severe chronic obstructive airway dis-eases, acute abdomen, coagulopathy and/ or infections of the injection site, instability of the injected joint, psori-atic skin manifestation at the injection site, periarticular calcification, non-vascularized bone necrosis, tendon rupture, Charcot-joint.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Morphine Sulfate
Morphine 3 mg intraarticular once at baseline
|
active intervention
Other Names:
|
Active Comparator: Triamcinolone
Triamcinolone 40 mg intraarticular once at baseline
|
active control
Other Names:
|
Placebo Comparator: Placebo
NaCl 0,9% 5 ml intraarticular at baseline
|
placebo control
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline
Time Frame: 1 week
|
Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7
Time Frame: 1 week
|
Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7
|
1 week
|
Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2
Time Frame: 2 weeks
|
Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2
|
2 weeks
|
daily activities at baseline, week 1 and 2
Time Frame: 2 weeks
|
daily activities at baseline, week 1 and 2
|
2 weeks
|
activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2
Time Frame: 2 weeks
|
activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2
|
2 weeks
|
WOMAC scale (before i.a. injections at baseline, week 1 and 2)
Time Frame: 2 weeks
|
WOMAC scale (before i.a.
injections and at the end of each week)
|
2 weeks
|
nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before i.a. medication at baseline and week 1),
Time Frame: 1 weeks
|
nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before and 7 days af-ter i.a.
medication),
|
1 weeks
|
supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2
Time Frame: 2 weeks
|
supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2
|
2 weeks
|
Any systemic (e.g. nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and week 2.
Time Frame: Screening, Baseline, week 1, week 2
|
Any systemic (e.g.
nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and 2.
|
Screening, Baseline, week 1, week 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hildrun Haibel, PD Dr, Charité CBF, Rheumatology, Berlin, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Analgesics, Opioid
- Narcotics
- Triamcinolone
- Morphine
Other Study ID Numbers
- NEUROIMPA2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Arthritis
-
NHS LothianNot yet recruitingOsteo Arthritis Knee | Arthropathy of Knee | Arthritis KneeUnited Kingdom
-
Zimmer BiometEnrolling by invitationOsteo Arthritis Knee | Knee Arthritis | Total Knee Arthroplasty | Total Knee Replacement | Monitoring Orthopedic DevicesUnited States
-
Loma Linda UniversityWithdrawnKnee Arthroscopy | Arthritis of Knee | Normal Knee
-
CorinActive, not recruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
CorinRecruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
CorinActive, not recruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
Medical University of WarsawCompletedOsteo Arthritis Knee | Knee Arthritis | Knee Pain ChronicPoland
-
Rehasport ClinicUnknownJoint Diseases | Knee Osteoarthritis | Osteo Arthritis Knee | Knee Arthritis | Knee Pain Chronic | Knee Pain Swelling | Knee DiseasePoland
-
Science and Research Centre KoperSlovenian Research AgencyCompletedOsteo Arthritis Knee | Knee ArthroplastySlovenia
-
The University of Tennessee, KnoxvilleMicroPort Orthopedics Inc.Not yet recruitingOsteo Arthritis Knee | Knee Injuries | Total Knee Arthroplasty | Knee ImlantUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States